G01N2333/29

VACCINES AND DIAGNOSTICS FOR THE EHRLICHIOSES
20170166628 · 2017-06-15 · ·

The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.

Rocky mountain spotted fever detection and treatment

Rocky Mountain Spotted Fever (RMSF) is a vector borne disease that is caused by Rickettsia rickettsii infection. It is challenging to identify the disease in dogs and other mammals due to the cross-reacting antibodies from non-pathogenic Rickettsia spp. Provided herein are compositions and methods for detection and treatment of Rocky Mountain spotted fever (RMSF). The compositions specifically detect Rickettsia rickettsii and do not cross-react with other Rickettsia species providing rapid and accurate detection and diagnosis of RMSF.

Immunoreactive peptides

Immunoreactive engineered polypeptides are provided. The engineered polypeptides can be used to diagnose or induce an immune response against E. chaffeensis or E. canis.

Peptides, devices, and methods for the detection of ehrlichia antibodies

The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions and mixtures comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic and/or granulocytic ehrlichiosis.

Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis

The present invention concerns gp36 immunoreactive compositions for E. canis and gp 47 immunoreactive compositions for E. chaffeensis. In particular, epitopes for E. canis gp36 and E. chaffeensis gp 47 are disclosed. In certain embodiments, the immunoreactive compositions comprise tandem repeats having carbohydrate moieties.

NOVEL ASSAYS FOR DETECTING ANALYTES IN SAMPLES AND KITS AND COMPOSITIONS RELATED THERETO
20170108494 · 2017-04-20 ·

The present invention provides methods of detecting analytes using particles having different physico-chemical properties, such as buoyancy, size, density, spectral characteristics, and/or binding properties, in solution-based sandwich assays and solution-based competition assays. The methods can be performed using rotors and bench-top centrifuges and provide for rapid, qualitative and quantitative detection of analytes. The present invention also provides kits that can be used to perform the methods, and mixtures containing particles suitable for the methods.

Immunoreactive glycoprotein GP19 Ehrlichia canis

The present invention concerns gp19 immunoreactive compositions for E. canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. canis gp19 are disclosed.

Immunoreactive glycoprotein GP19 of ehrlichia canis

The present invention concerns gp19 immunoreactive compositions for E. canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. canis gp19 are disclosed.

Vaccines and diagnostics for the ehrlichioses

The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.

Vaccines and diagnostics for the ehrlichioses

The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.